-$0.04 EPS Expected for OrganiGram Holdings Inc. (NASDAQ:OGI) This Quarter

Wall Street brokerages predict that OrganiGram Holdings Inc. (NASDAQ:OGI) will report earnings per share (EPS) of ($0.04) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for OrganiGram’s earnings, with the lowest EPS estimate coming in at ($0.05) and the highest estimate coming in at ($0.03). OrganiGram posted earnings of ($0.03) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 33.3%. The company is scheduled to report its next earnings report on Monday, November 29th.

On average, analysts expect that OrganiGram will report full year earnings of ($0.28) per share for the current fiscal year, with EPS estimates ranging from ($0.40) to ($0.18). For the next financial year, analysts anticipate that the business will post earnings of ($0.11) per share, with EPS estimates ranging from ($0.15) to ($0.06). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow OrganiGram.

OrganiGram (NASDAQ:OGI) last released its quarterly earnings data on Monday, July 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. OrganiGram had a negative net margin of 190.24% and a negative return on equity of 19.91%. The firm had revenue of $16.55 million for the quarter, compared to analysts’ expectations of $13.95 million.

A number of equities analysts have issued reports on OGI shares. Zacks Investment Research cut shares of OrganiGram from a “hold” rating to a “sell” rating in a research report on Friday, September 3rd. Atb Cap Markets restated a “sector perform” rating on shares of OrganiGram in a research report on Friday, July 23rd. Stifel Nicolaus reduced their price target on shares of OrganiGram from C$4.00 to C$3.75 and set a “hold” rating on the stock in a research report on Thursday, July 15th. Finally, CIBC reduced their price target on shares of OrganiGram from C$4.00 to C$3.50 and set a “neutral” rating on the stock in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.21.

Shares of OGI stock traded up $0.04 during mid-day trading on Monday, reaching $2.46. The stock had a trading volume of 170,694 shares, compared to its average volume of 13,136,897. The stock’s 50-day moving average price is $2.55 and its two-hundred day moving average price is $2.84. OrganiGram has a 52-week low of $1.01 and a 52-week high of $6.45. The firm has a market capitalization of $737.54 million, a PE ratio of -4.69 and a beta of 0.10.

Large investors have recently bought and sold shares of the stock. SRS Capital Advisors Inc. bought a new position in shares of OrganiGram in the second quarter worth approximately $29,000. Chartist Inc. CA bought a new position in shares of OrganiGram in the second quarter worth approximately $29,000. Bank of New York Mellon Corp bought a new position in shares of OrganiGram in the second quarter worth approximately $29,000. Advisor Resource Council bought a new position in shares of OrganiGram in the second quarter worth approximately $34,000. Finally, Marcum Wealth LLC bought a new position in shares of OrganiGram in the first quarter worth approximately $35,000. 13.76% of the stock is currently owned by institutional investors and hedge funds.

About OrganiGram

Further Reading: How to read a candlestick chart

Get a free copy of the Zacks research report on OrganiGram (OGI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OrganiGram (NASDAQ:OGI)

Receive News & Ratings for OrganiGram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrganiGram and related companies with MarketBeat.com's FREE daily email newsletter.